Malignant  ||| S:0 E:10 ||| JJ
mixed  ||| S:10 E:16 ||| JJ
tumors  ||| S:16 E:23 ||| NNS
of  ||| S:23 E:26 ||| IN
the  ||| S:26 E:30 ||| DT
parotid  ||| S:30 E:38 ||| JJ
gland ||| S:38 E:43 ||| NN
:  ||| S:43 E:45 ||| :
a  ||| S:45 E:47 ||| DT
review  ||| S:47 E:54 ||| NN
of  ||| S:54 E:57 ||| IN
the  ||| S:57 E:61 ||| DT
Department  ||| S:61 E:72 ||| NNP
of  ||| S:72 E:75 ||| IN
Otolaryngology  ||| S:75 E:90 ||| NNP
Medical  ||| S:90 E:98 ||| NNP
University  ||| S:98 E:109 ||| NNP
of  ||| S:109 E:112 ||| IN
Warsaw  ||| S:112 E:119 ||| NNP
experience  ||| S:119 E:130 ||| FW
Pleomorphic  ||| S:130 E:142 ||| FW
adenoma  ||| S:142 E:150 ||| FW
( ||| S:150 E:151 ||| -LRB-
PA ||| S:151 E:153 ||| NNP
) ||| S:153 E:154 ||| -RRB-
,  ||| S:154 E:156 ||| ,
or  ||| S:156 E:159 ||| CC
benign  ||| S:159 E:166 ||| JJ
mixed  ||| S:166 E:172 ||| JJ
tumor ||| S:172 E:177 ||| NN
,  ||| S:177 E:179 ||| ,
is  ||| S:179 E:182 ||| VBZ
the  ||| S:182 E:186 ||| DT
most  ||| S:186 E:191 ||| RBS
common  ||| S:191 E:198 ||| JJ
salivary  ||| S:198 E:207 ||| JJ
gland  ||| S:207 E:213 ||| JJ
neoplasm ||| S:213 E:221 ||| NN
.  ||| S:221 E:223 ||| .
One  ||| S:223 E:227 ||| CD
of  ||| S:227 E:230 ||| IN
the  ||| S:230 E:234 ||| DT
factors  ||| S:234 E:242 ||| NNS
influencing  ||| S:242 E:254 ||| VBG
the  ||| S:254 E:258 ||| DT
management  ||| S:258 E:269 ||| NN
strategy  ||| S:269 E:278 ||| NN
in  ||| S:278 E:281 ||| IN
parotid  ||| S:281 E:289 ||| JJ
PA  ||| S:289 E:292 ||| NNP
is  ||| S:292 E:295 ||| VBZ
the  ||| S:295 E:299 ||| DT
risk  ||| S:299 E:304 ||| NN
of  ||| S:304 E:307 ||| IN
malignant  ||| S:307 E:317 ||| JJ
transformation  ||| S:317 E:332 ||| NN
of  ||| S:332 E:335 ||| IN
this  ||| S:335 E:340 ||| DT
tumor ||| S:340 E:345 ||| NN
.  ||| S:345 E:347 ||| .
The  ||| S:347 E:351 ||| DT
objective  ||| S:351 E:361 ||| NN
of  ||| S:361 E:364 ||| IN
this  ||| S:364 E:369 ||| DT
study  ||| S:369 E:375 ||| NN
was  ||| S:375 E:379 ||| VBD
the  ||| S:379 E:383 ||| DT
clinical  ||| S:383 E:392 ||| JJ
and  ||| S:392 E:396 ||| CC
pathological  ||| S:396 E:409 ||| JJ
analysis  ||| S:409 E:418 ||| NN
of  ||| S:418 E:421 ||| IN
malignant  ||| S:421 E:431 ||| JJ
mixed  ||| S:431 E:437 ||| JJ
tumors  ||| S:437 E:444 ||| NNS
treated  ||| S:444 E:452 ||| VBN
surgically  ||| S:452 E:463 ||| RB
at  ||| S:463 E:466 ||| IN
the  ||| S:466 E:470 ||| DT
Department  ||| S:470 E:481 ||| NNP
of  ||| S:481 E:484 ||| IN
Otolaryngology ||| S:484 E:498 ||| NNP
,  ||| S:498 E:500 ||| ,
Medical  ||| S:500 E:508 ||| NNP
University  ||| S:508 E:519 ||| NNP
of  ||| S:519 E:522 ||| IN
Warsaw ||| S:522 E:528 ||| NNP
.  ||| S:528 E:530 ||| .
Retrospectively  ||| S:530 E:546 ||| JJ
analysed  ||| S:546 E:555 ||| JJ
clinical  ||| S:555 E:564 ||| JJ
material  ||| S:564 E:573 ||| NN
included  ||| S:573 E:582 ||| VBD
12  ||| S:582 E:585 ||| CD
patients  ||| S:585 E:594 ||| NNS
with  ||| S:594 E:599 ||| IN
malignant  ||| S:599 E:609 ||| JJ
mixed  ||| S:609 E:615 ||| JJ
tumors  ||| S:615 E:622 ||| NNS
selected  ||| S:622 E:631 ||| VBN
from  ||| S:631 E:636 ||| IN
the  ||| S:636 E:640 ||| DT
group  ||| S:640 E:646 ||| NN
of  ||| S:646 E:649 ||| IN
423  ||| S:649 E:653 ||| CD
patients  ||| S:653 E:662 ||| NNS
who  ||| S:662 E:666 ||| WP
underwent  ||| S:666 E:676 ||| VBD
surgical  ||| S:676 E:685 ||| JJ
treatment  ||| S:685 E:695 ||| NN
for  ||| S:695 E:699 ||| IN
parotid  ||| S:699 E:707 ||| JJ
pleomorphic  ||| S:707 E:719 ||| JJ
adenoma  ||| S:719 E:727 ||| NN
at  ||| S:727 E:730 ||| IN
the  ||| S:730 E:734 ||| DT
Department  ||| S:734 E:745 ||| NNP
of  ||| S:745 E:748 ||| IN
Otolaryngology ||| S:748 E:762 ||| NNP
,  ||| S:762 E:764 ||| ,
Medical  ||| S:764 E:772 ||| NNP
University  ||| S:772 E:783 ||| NNP
of  ||| S:783 E:786 ||| IN
Warsaw ||| S:786 E:792 ||| NNP
,  ||| S:792 E:794 ||| ,
between  ||| S:794 E:802 ||| IN
January  ||| S:802 E:810 ||| NNP
1988  ||| S:810 E:815 ||| CD
and  ||| S:815 E:819 ||| CC
June  ||| S:819 E:824 ||| NNP
2010 ||| S:824 E:828 ||| CD
.  ||| S:828 E:830 ||| .
There  ||| S:830 E:836 ||| EX
were  ||| S:836 E:841 ||| VBD
7  ||| S:841 E:843 ||| CD
women  ||| S:843 E:849 ||| NNS
and  ||| S:849 E:853 ||| CC
5  ||| S:853 E:855 ||| CD
men ||| S:855 E:858 ||| NNS
;  ||| S:858 E:860 ||| :
age  ||| S:860 E:864 ||| NN
ranged  ||| S:864 E:871 ||| VBD
from  ||| S:871 E:876 ||| IN
39  ||| S:876 E:879 ||| CD
to  ||| S:879 E:882 ||| TO
67  ||| S:882 E:885 ||| CD
years ||| S:885 E:890 ||| NNS
,  ||| S:890 E:892 ||| ,
with  ||| S:892 E:897 ||| IN
a  ||| S:897 E:899 ||| DT
mean  ||| S:899 E:904 ||| NN
of  ||| S:904 E:907 ||| IN
56  ||| S:907 E:910 ||| CD
years ||| S:910 E:915 ||| NNS
.  ||| S:915 E:917 ||| .
The  ||| S:917 E:921 ||| DT
following  ||| S:921 E:931 ||| JJ
parameters  ||| S:931 E:942 ||| NNS
were  ||| S:942 E:947 ||| VBD
analysed ||| S:947 E:955 ||| VBN
:  ||| S:955 E:957 ||| :
demographic  ||| S:957 E:969 ||| JJ
data ||| S:969 E:973 ||| NNS
,  ||| S:973 E:975 ||| ,
symptoms  ||| S:975 E:984 ||| NNS
and  ||| S:984 E:988 ||| CC
disease  ||| S:988 E:996 ||| NN
duration ||| S:996 E:1004 ||| NN
,  ||| S:1004 E:1006 ||| ,
results  ||| S:1006 E:1014 ||| NNS
of  ||| S:1014 E:1017 ||| IN
diagnostic  ||| S:1017 E:1028 ||| JJ
tests ||| S:1028 E:1033 ||| NNS
,  ||| S:1033 E:1035 ||| ,
intraoperative  ||| S:1035 E:1050 ||| JJ
data ||| S:1050 E:1054 ||| NNS
,  ||| S:1054 E:1056 ||| ,
results  ||| S:1056 E:1064 ||| NNS
of  ||| S:1064 E:1067 ||| IN
histopathological  ||| S:1067 E:1085 ||| JJ
examination ||| S:1085 E:1096 ||| NN
,  ||| S:1096 E:1098 ||| ,
and  ||| S:1098 E:1102 ||| CC
adjunctive  ||| S:1102 E:1113 ||| JJ
therapy ||| S:1113 E:1120 ||| NN
.  ||| S:1120 E:1122 ||| .
Four  ||| S:1122 E:1127 ||| CD
patients  ||| S:1127 E:1136 ||| NNS
with  ||| S:1136 E:1141 ||| IN
a  ||| S:1141 E:1143 ||| DT
follow-up  ||| S:1143 E:1153 ||| JJ
shorter  ||| S:1153 E:1161 ||| NN
than  ||| S:1161 E:1166 ||| IN
5  ||| S:1166 E:1168 ||| CD
years  ||| S:1168 E:1174 ||| NNS
were  ||| S:1174 E:1179 ||| VBD
excluded  ||| S:1179 E:1188 ||| VBN
from  ||| S:1188 E:1193 ||| IN
the  ||| S:1193 E:1197 ||| DT
analysis  ||| S:1197 E:1206 ||| NN
of  ||| S:1206 E:1209 ||| IN
treatment  ||| S:1209 E:1219 ||| NN
results ||| S:1219 E:1226 ||| NNS
.  ||| S:1226 E:1228 ||| .
A  ||| S:1228 E:1230 ||| DT
group  ||| S:1230 E:1236 ||| NN
of  ||| S:1236 E:1239 ||| IN
12  ||| S:1239 E:1242 ||| CD
patients  ||| S:1242 E:1251 ||| NNS
with  ||| S:1251 E:1256 ||| IN
malignant  ||| S:1256 E:1266 ||| JJ
mixed  ||| S:1266 E:1272 ||| JJ
tumours  ||| S:1272 E:1280 ||| NN
included  ||| S:1280 E:1289 ||| VBD
10  ||| S:1289 E:1292 ||| CD
( ||| S:1292 E:1293 ||| -LRB-
83.3 ||| S:1293 E:1297 ||| CD
% ||| S:1297 E:1298 ||| NN
)  ||| S:1298 E:1300 ||| -RRB-
cases  ||| S:1300 E:1306 ||| NNS
of  ||| S:1306 E:1309 ||| IN
a  ||| S:1309 E:1311 ||| DT
primary  ||| S:1311 E:1319 ||| JJ
tumor  ||| S:1319 E:1325 ||| NN
and  ||| S:1325 E:1329 ||| CC
2  ||| S:1329 E:1331 ||| CD
( ||| S:1331 E:1332 ||| -LRB-
16.7 ||| S:1332 E:1336 ||| CD
% ||| S:1336 E:1337 ||| NN
)  ||| S:1337 E:1339 ||| -RRB-
cases  ||| S:1339 E:1345 ||| NNS
of  ||| S:1345 E:1348 ||| IN
a  ||| S:1348 E:1350 ||| DT
recurrent  ||| S:1350 E:1360 ||| JJ
tumor ||| S:1360 E:1365 ||| NN
.  ||| S:1365 E:1367 ||| .
In  ||| S:1367 E:1370 ||| IN
the  ||| S:1370 E:1374 ||| DT
complete  ||| S:1374 E:1383 ||| JJ
study  ||| S:1383 E:1389 ||| NN
sample  ||| S:1389 E:1396 ||| NN
( ||| S:1396 E:1397 ||| -LRB-
n=423 ||| S:1397 E:1402 ||| NNP
) ||| S:1402 E:1403 ||| -RRB-
,  ||| S:1403 E:1405 ||| ,
patients  ||| S:1405 E:1414 ||| NNS
with  ||| S:1414 E:1419 ||| IN
malignant  ||| S:1419 E:1429 ||| JJ
mixed  ||| S:1429 E:1435 ||| JJ
tumor  ||| S:1435 E:1441 ||| NN
comprised ||| S:1441 E:1450 ||| NNS
:  ||| S:1450 E:1452 ||| :
2.8 ||| S:1452 E:1455 ||| CD
%  ||| S:1455 E:1457 ||| NN
of  ||| S:1457 E:1460 ||| IN
all  ||| S:1460 E:1464 ||| DT
patients ||| S:1464 E:1472 ||| NNS
,  ||| S:1472 E:1474 ||| ,
2.5 ||| S:1474 E:1477 ||| CD
%  ||| S:1477 E:1479 ||| NN
of  ||| S:1479 E:1482 ||| IN
patients  ||| S:1482 E:1491 ||| NNS
with  ||| S:1491 E:1496 ||| IN
primary  ||| S:1496 E:1504 ||| JJ
PA  ||| S:1504 E:1507 ||| NNP
and  ||| S:1507 E:1511 ||| CC
5.1 ||| S:1511 E:1514 ||| CD
%  ||| S:1514 E:1516 ||| NN
of  ||| S:1516 E:1519 ||| IN
patients  ||| S:1519 E:1528 ||| NNS
with  ||| S:1528 E:1533 ||| IN
recurrent  ||| S:1533 E:1543 ||| JJ
PA ||| S:1543 E:1545 ||| NNP
.  ||| S:1545 E:1547 ||| .
Patients  ||| S:1547 E:1556 ||| NNS
with  ||| S:1556 E:1561 ||| IN
malignant  ||| S:1561 E:1571 ||| JJ
mixed  ||| S:1571 E:1577 ||| JJ
tumor  ||| S:1577 E:1583 ||| NN
were  ||| S:1583 E:1588 ||| VBD
significantly  ||| S:1588 E:1602 ||| RB
older  ||| S:1602 E:1608 ||| JJR
than  ||| S:1608 E:1613 ||| IN
patients  ||| S:1613 E:1622 ||| NNS
with  ||| S:1622 E:1627 ||| IN
benign  ||| S:1627 E:1634 ||| JJ
PA  ||| S:1634 E:1637 ||| NNP
( ||| S:1637 E:1638 ||| -LRB-
an  ||| S:1638 E:1641 ||| DT
average  ||| S:1641 E:1649 ||| JJ
patient  ||| S:1649 E:1657 ||| NN
age  ||| S:1657 E:1661 ||| NN
was  ||| S:1661 E:1665 ||| VBD
56.0  ||| S:1665 E:1670 ||| CD
and  ||| S:1670 E:1674 ||| CC
43.2  ||| S:1674 E:1679 ||| CD
years ||| S:1679 E:1684 ||| NNS
,  ||| S:1684 E:1686 ||| ,
respectively  ||| S:1686 E:1699 ||| RB
p  ||| S:1699 E:1700 ||| CD
< ||| S:1700 E:1701 ||| SYM
0.001 ||| S:1701 E:1706 ||| CD
) ||| S:1706 E:1707 ||| -RRB-
.  ||| S:1707 E:1709 ||| .
83.3 ||| S:1709 E:1713 ||| CD
%  ||| S:1713 E:1715 ||| NN
( ||| S:1715 E:1716 ||| -LRB-
n=10 ||| S:1716 E:1720 ||| NNP
)  ||| S:1720 E:1722 ||| -RRB-
patients  ||| S:1722 E:1731 ||| NNS
were  ||| S:1731 E:1736 ||| VBD
older  ||| S:1736 E:1742 ||| JJR
than  ||| S:1742 E:1747 ||| IN
50  ||| S:1747 E:1750 ||| CD
years ||| S:1750 E:1755 ||| NNS
.  ||| S:1755 E:1757 ||| .
An  ||| S:1757 E:1760 ||| DT
average  ||| S:1760 E:1768 ||| JJ
disease  ||| S:1768 E:1776 ||| NN
duration  ||| S:1776 E:1785 ||| NN
was  ||| S:1785 E:1789 ||| VBD
longer  ||| S:1789 E:1796 ||| RBR
in  ||| S:1796 E:1799 ||| IN
patients  ||| S:1799 E:1808 ||| NNS
with  ||| S:1808 E:1813 ||| IN
malignant  ||| S:1813 E:1823 ||| JJ
tumors ||| S:1823 E:1829 ||| NNS
.  ||| S:1829 E:1831 ||| .
Considering  ||| S:1831 E:1843 ||| VBG
all  ||| S:1843 E:1847 ||| DT
data  ||| S:1847 E:1852 ||| NNS
from  ||| S:1852 E:1857 ||| IN
preoperative  ||| S:1857 E:1870 ||| JJ
patient  ||| S:1870 E:1878 ||| NN
assessment  ||| S:1878 E:1889 ||| NN
( ||| S:1889 E:1890 ||| -LRB-
medical  ||| S:1890 E:1898 ||| JJ
history ||| S:1898 E:1905 ||| NN
,  ||| S:1905 E:1907 ||| ,
physical  ||| S:1907 E:1916 ||| JJ
examination ||| S:1916 E:1927 ||| NN
,  ||| S:1927 E:1929 ||| ,
FNAB ||| S:1929 E:1933 ||| NNP
,  ||| S:1933 E:1935 ||| ,
imaging  ||| S:1935 E:1943 ||| JJ
studies ||| S:1943 E:1950 ||| NNS
) ||| S:1950 E:1951 ||| -RRB-
,  ||| S:1951 E:1953 ||| ,
a  ||| S:1953 E:1955 ||| DT
preliminary  ||| S:1955 E:1967 ||| JJ
diagnosis  ||| S:1967 E:1977 ||| NN
of  ||| S:1977 E:1980 ||| IN
malignant  ||| S:1980 E:1990 ||| JJ
disease  ||| S:1990 E:1998 ||| NN
was  ||| S:1998 E:2002 ||| VBD
made  ||| S:2002 E:2007 ||| VBN
in  ||| S:2007 E:2010 ||| IN
6  ||| S:2010 E:2012 ||| CD
( ||| S:2012 E:2013 ||| -LRB-
50 ||| S:2013 E:2015 ||| CD
% ||| S:2015 E:2016 ||| NN
)  ||| S:2016 E:2018 ||| -RRB-
patients ||| S:2018 E:2026 ||| NNS
.  ||| S:2026 E:2028 ||| .
All  ||| S:2028 E:2032 ||| DT
patients  ||| S:2032 E:2041 ||| NNS
were  ||| S:2041 E:2046 ||| VBD
treated  ||| S:2046 E:2054 ||| VBN
surgically  ||| S:2054 E:2065 ||| NNS
and  ||| S:2065 E:2069 ||| CC
10  ||| S:2069 E:2072 ||| CD
also  ||| S:2072 E:2077 ||| RB
had  ||| S:2077 E:2081 ||| VBD
radiation  ||| S:2081 E:2091 ||| NN
therapy ||| S:2091 E:2098 ||| NN
.  ||| S:2098 E:2100 ||| .
The  ||| S:2100 E:2104 ||| DT
group  ||| S:2104 E:2110 ||| NN
of  ||| S:2110 E:2113 ||| IN
patients  ||| S:2113 E:2122 ||| NNS
( ||| S:2122 E:2123 ||| -LRB-
n=8 ||| S:2123 E:2126 ||| NNP
) ||| S:2126 E:2127 ||| -RRB-
,  ||| S:2127 E:2129 ||| ,
subjected  ||| S:2129 E:2139 ||| VBN
to  ||| S:2139 E:2142 ||| TO
evaluation  ||| S:2142 E:2153 ||| NN
of  ||| S:2153 E:2156 ||| IN
treatment  ||| S:2156 E:2166 ||| NN
results ||| S:2166 E:2173 ||| NNS
,  ||| S:2173 E:2175 ||| ,
included  ||| S:2175 E:2184 ||| VBD
three  ||| S:2184 E:2190 ||| CD
patients  ||| S:2190 E:2199 ||| NNS
with  ||| S:2199 E:2204 ||| IN
non-invasive  ||| S:2204 E:2217 ||| JJ
carcinoma  ||| S:2217 E:2227 ||| NN
and  ||| S:2227 E:2231 ||| CC
five  ||| S:2231 E:2236 ||| CD
patients  ||| S:2236 E:2245 ||| NNS
with  ||| S:2245 E:2250 ||| IN
invasive  ||| S:2250 E:2259 ||| JJ
carcinoma ||| S:2259 E:2268 ||| NN
.  ||| S:2268 E:2270 ||| .
All  ||| S:2270 E:2274 ||| DT
patients  ||| S:2274 E:2283 ||| NNS
with  ||| S:2283 E:2288 ||| IN
non-invasive  ||| S:2288 E:2301 ||| JJ
carcinoma  ||| S:2301 E:2311 ||| NN
were  ||| S:2311 E:2316 ||| VBD
free  ||| S:2316 E:2321 ||| JJ
from  ||| S:2321 E:2326 ||| IN
disease  ||| S:2326 E:2334 ||| NN
symptoms  ||| S:2334 E:2343 ||| NNS
during  ||| S:2343 E:2350 ||| IN
the  ||| S:2350 E:2354 ||| DT
follow-up  ||| S:2354 E:2364 ||| JJ
of  ||| S:2364 E:2367 ||| IN
9  ||| S:2367 E:2369 ||| CD
to  ||| S:2369 E:2372 ||| TO
21  ||| S:2372 E:2375 ||| CD
years  ||| S:2375 E:2381 ||| NNS
after  ||| S:2381 E:2387 ||| IN
the  ||| S:2387 E:2391 ||| DT
treatment ||| S:2391 E:2400 ||| NN
.  ||| S:2400 E:2402 ||| .
Five-year  ||| S:2402 E:2412 ||| JJ
survival  ||| S:2412 E:2421 ||| NN
was  ||| S:2421 E:2425 ||| VBD
80 ||| S:2425 E:2427 ||| CD
%  ||| S:2427 E:2429 ||| NN
( ||| S:2429 E:2430 ||| -LRB-
4  ||| S:2430 E:2432 ||| CD
of  ||| S:2432 E:2435 ||| IN
5  ||| S:2435 E:2437 ||| CD
patients ||| S:2437 E:2445 ||| NNS
)  ||| S:2445 E:2447 ||| -RRB-
in  ||| S:2447 E:2450 ||| IN
a  ||| S:2450 E:2452 ||| DT
group  ||| S:2452 E:2458 ||| NN
of  ||| S:2458 E:2461 ||| IN
patients  ||| S:2461 E:2470 ||| NNS
with  ||| S:2470 E:2475 ||| IN
invasive  ||| S:2475 E:2484 ||| JJ
carcinoma ||| S:2484 E:2493 ||| NN
.  ||| S:2493 E:2495 ||| .
The  ||| S:2495 E:2499 ||| DT
rate  ||| S:2499 E:2504 ||| NN
of  ||| S:2504 E:2507 ||| IN
death  ||| S:2507 E:2513 ||| NN
for  ||| S:2513 E:2517 ||| IN
the  ||| S:2517 E:2521 ||| DT
underlying  ||| S:2521 E:2532 ||| JJ
disease  ||| S:2532 E:2540 ||| NN
was  ||| S:2540 E:2544 ||| VBD
the  ||| S:2544 E:2548 ||| DT
same  ||| S:2548 E:2553 ||| JJ
( ||| S:2553 E:2554 ||| -LRB-
80 ||| S:2554 E:2556 ||| CD
% ||| S:2556 E:2557 ||| NN
) ||| S:2557 E:2558 ||| -RRB-
.  ||| S:2558 E:2560 ||| .
An  ||| S:2560 E:2563 ||| DT
overall  ||| S:2563 E:2571 ||| JJ
5-year  ||| S:2571 E:2578 ||| CD
survival  ||| S:2578 E:2587 ||| NN
in  ||| S:2587 E:2590 ||| IN
patients  ||| S:2590 E:2599 ||| NNS
with  ||| S:2599 E:2604 ||| IN
malignant  ||| S:2604 E:2614 ||| JJ
mixed  ||| S:2614 E:2620 ||| JJ
tumor  ||| S:2620 E:2626 ||| NN
was  ||| S:2626 E:2630 ||| VBD
87.5 ||| S:2630 E:2634 ||| CD
% ||| S:2634 E:2635 ||| NN
.  ||| S:2635 E:2637 ||| .
1 ||| S:2637 E:2638 ||| LS
.  ||| S:2638 E:2640 ||| .
Malignant  ||| S:2640 E:2650 ||| JJ
transformation  ||| S:2650 E:2665 ||| NN
of  ||| S:2665 E:2668 ||| IN
pleomorphic  ||| S:2668 E:2680 ||| JJ
adenoma  ||| S:2680 E:2688 ||| NN
more  ||| S:2688 E:2693 ||| RBR
frequently  ||| S:2693 E:2704 ||| RB
occurs  ||| S:2704 E:2711 ||| VBZ
in  ||| S:2711 E:2714 ||| IN
recurrent  ||| S:2714 E:2724 ||| JJ
tumors  ||| S:2724 E:2731 ||| NNS
and  ||| S:2731 E:2735 ||| CC
in  ||| S:2735 E:2738 ||| IN
older  ||| S:2738 E:2744 ||| JJR
patients.  ||| S:2744 E:2754 ||| CD
2 ||| S:2754 E:2755 ||| CD
.  ||| S:2755 E:2757 ||| .
Uncharacteristic  ||| S:2757 E:2774 ||| JJ
clinical  ||| S:2774 E:2783 ||| JJ
picture  ||| S:2783 E:2791 ||| NN
of  ||| S:2791 E:2794 ||| IN
malignant  ||| S:2794 E:2804 ||| JJ
mixed  ||| S:2804 E:2810 ||| JJ
tumors  ||| S:2810 E:2817 ||| NN
allows  ||| S:2817 E:2824 ||| VBZ
to  ||| S:2824 E:2827 ||| TO
make  ||| S:2827 E:2832 ||| VB
an  ||| S:2832 E:2835 ||| DT
accurate  ||| S:2835 E:2844 ||| JJ
initial  ||| S:2844 E:2852 ||| JJ
diagnosis  ||| S:2852 E:2862 ||| NN
only  ||| S:2862 E:2867 ||| RB
in  ||| S:2867 E:2870 ||| IN
half  ||| S:2870 E:2875 ||| NN
of  ||| S:2875 E:2878 ||| IN
the  ||| S:2878 E:2882 ||| DT
patients.  ||| S:2882 E:2892 ||| CD
3 ||| S:2892 E:2893 ||| CD
.  ||| S:2893 E:2895 ||| .
Extracapsular  ||| S:2895 E:2909 ||| JJ
cancer  ||| S:2909 E:2916 ||| NN
invasion  ||| S:2916 E:2925 ||| NN
is  ||| S:2925 E:2928 ||| VBZ
a  ||| S:2928 E:2930 ||| DT
vital  ||| S:2930 E:2936 ||| JJ
prognostic  ||| S:2936 E:2947 ||| JJ
factor ||| S:2947 E:2953 ||| NN
.  ||| S:2953 E:2955 ||| .
Overall  ||| S:2955 E:2963 ||| RB
5-year  ||| S:2963 E:2970 ||| CD
survival  ||| S:2970 E:2979 ||| NN
for  ||| S:2979 E:2983 ||| IN
invasive  ||| S:2983 E:2992 ||| NN
and  ||| S:2992 E:2996 ||| CC
noninvasive  ||| S:2996 E:3008 ||| JJ
carcinoma  ||| S:3008 E:3018 ||| NN
was  ||| S:3018 E:3022 ||| VBD
80  ||| S:3022 E:3025 ||| CD
%  ||| S:3025 E:3027 ||| NN
and  ||| S:3027 E:3031 ||| CC
100  ||| S:3031 E:3035 ||| CD
%  ||| S:3035 E:3037 ||| NN
respectively ||| S:3037 E:3049 ||| RB
.  ||| S:3049 E:3051 ||| .
